Medical Oncology at Zhongshan Hospital Shanghai | CMCS

Comprehensive Cancer Treatment in Shanghai

The Department of Medical Oncology at Fudan University's Zhongshan Hospital is one of China's leading centers for systemic cancer treatment, offering the full spectrum of chemotherapy, targeted therapy, immunotherapy, and clinical trial access for patients with solid tumors and hematological malignancies. Integrated within one of China's premier academic medical centers, the department combines clinical excellence with cutting-edge research to deliver personalized, evidence-based cancer care to patients from across China and internationally.

For international patients navigating a cancer diagnosis, China Medical Concierge Shanghai (CMCS) provides end-to-end support — from medical record translation and molecular report interpretation to specialist scheduling, on-site accompaniment, and post-treatment coordination.

About the Department

Zhongshan Hospital's medical oncology department operates as part of a comprehensive cancer center that integrates surgical oncology, radiation oncology, interventional oncology, and medical oncology under one roof. This multidisciplinary structure ensures that every cancer patient benefits from a collaborative, tumor-board-driven treatment approach rather than a single-specialty perspective.

The department maintains an active clinical trials program, participating in national and international studies evaluating novel targeted agents, immunotherapy combinations, antibody-drug conjugates (ADCs), and cell therapies. For patients who have exhausted standard treatment options or who seek access to next-generation therapies, Zhongshan's trials program represents a significant advantage.

A dedicated molecular pathology and genomics service performs comprehensive tumor profiling — including next-generation sequencing (NGS) panels, liquid biopsy, and biomarker testing — to guide precision oncology treatment decisions for every eligible patient.

Cancers Treated

• Lung Cancer — NSCLC and SCLC; EGFR, ALK, ROS1, KRAS, MET, and HER2-targeted therapy; PD-1/PD-L1 immunotherapy
• Colorectal Cancer — FOLFOX, FOLFIRI, CAPOX regimens; anti-VEGF and anti-EGFR biologics; MSI-H immunotherapy; KRAS/NRAS/BRAF-guided therapy
• Gastric & Gastroesophageal Junction Cancer — HER2-targeted therapy (trastuzumab, trastuzumab deruxtecan); PD-1 immunotherapy; FLOT and XELOX regimens
• Hepatocellular Carcinoma (HCC) — Sorafenib, lenvatinib, regorafenib; atezolizumab + bevacizumab; HAIC combination strategies
• Pancreatic Cancer — FOLFIRINOX, gemcitabine + nab-paclitaxel; BRCA-targeted PARP inhibitors; clinical trial access
• Breast Cancer — HER2-targeted therapy (trastuzumab, pertuzumab, T-DM1, T-DXd); CDK4/6 inhibitors for HR+ disease; PARP inhibitors for BRCA-mutated TNBC; immunotherapy
• Esophageal Cancer — Perioperative chemotherapy; PD-1 immunotherapy combinations; definitive chemoradiation
• Biliary Tract Cancer — Gemcitabine + cisplatin; IDH1/FGFR2-targeted therapy; PD-1 combinations
• Renal Cell Carcinoma — VEGFR-targeted therapy (sunitinib, pazopanib, cabozantinib); PD-1/CTLA-4 combination immunotherapy
• Bladder Cancer — Platinum-based chemotherapy; PD-1/PD-L1 immunotherapy; enfortumab vedotin (ADC)
• Ovarian Cancer — Platinum-based chemotherapy; PARP inhibitors (olaparib, niraparib) for BRCA-mutated and HRD-positive disease; bevacizumab
• Cervical & Endometrial Cancer — Platinum-based regimens; pembrolizumab for MSI-H/TMB-H tumors; lenvatinib combinations
• Thyroid Cancer — Radioiodine therapy coordination; lenvatinib and sorafenib for radioiodine-refractory DTC; RET inhibitors for medullary thyroid cancer
• Neuroendocrine Tumors (NETs) — Somatostatin analogues; everolimus; sunitinib; peptide receptor radionuclide therapy (PRRT) coordination
• Unknown Primary Cancer — Comprehensive molecular profiling to guide tissue-agnostic and site-specific treatment

Precision Oncology & Molecular Profiling

Zhongshan Hospital's oncology program is built on a foundation of precision medicine. Every eligible patient undergoes comprehensive molecular profiling to identify actionable mutations, predictive biomarkers, and potential clinical trial eligibility:

• Next-Generation Sequencing (NGS) — Comprehensive tumor genomic profiling covering hundreds of cancer-relevant genes to identify targetable alterations
• Liquid Biopsy (ctDNA) — Blood-based tumor DNA analysis for treatment monitoring, resistance mechanism identification, and minimal residual disease detection
• PD-L1 & TMB Testing — Immunotherapy biomarker assessment to predict response to checkpoint inhibitors
• MSI/MMR Testing — Mismatch repair deficiency testing for immunotherapy eligibility across tumor types
• HER2, EGFR, ALK, ROS1, KRAS, BRAF, FGFR, IDH Testing — Standard and extended biomarker panels for targeted therapy selection
• Germline Testing — BRCA1/2 and other hereditary cancer gene testing with genetic counseling

Immunotherapy & Novel Therapies

Zhongshan's medical oncology team has extensive experience with the full range of approved immunotherapy and novel targeted agents, including:

• PD-1/PD-L1 Checkpoint Inhibitors — Pembrolizumab, nivolumab, atezolizumab, sintilimab, camrelizumab, tislelizumab, and other approved agents
• CTLA-4 Inhibitors — Ipilimumab in combination regimens for melanoma, RCC, and other tumors
• Antibody-Drug Conjugates (ADCs) — Trastuzumab deruxtecan (T-DXd), enfortumab vedotin, sacituzumab govitecan, and emerging ADC agents
• Bispecific Antibodies — Emerging bispecific T-cell engagers and other novel immunological agents through clinical trials
• CAR-T Cell Therapy — Coordination of CAR-T therapy for eligible hematological malignancy patients through Zhongshan's affiliated hematology program

Multidisciplinary Tumor Boards

Every complex cancer case at Zhongshan is reviewed by a disease-specific multidisciplinary tumor board (MDT) comprising medical oncologists, surgical oncologists, radiation oncologists, radiologists, pathologists, and molecular biologists. Disease-specific MDTs cover lung cancer, GI cancers, hepatobiliary cancers, breast cancer, gynecological cancers, urological cancers, and rare tumors.

For international patients, CMCS can facilitate remote MDT case submission, allowing your case to be reviewed by Zhongshan's specialists before you travel to Shanghai — ensuring that a treatment plan is ready from the moment you arrive.

Why International Patients Choose Zhongshan Medical Oncology

• Precision Medicine Leadership — Comprehensive NGS profiling and liquid biopsy as standard of care for eligible patients
• Clinical Trial Access — Active participation in national and international trials providing access to next-generation therapies
• Full Immunotherapy Portfolio — Experience with all approved PD-1/PD-L1 agents, ADCs, and emerging novel therapies
• Multidisciplinary Integration — Disease-specific tumor boards ensuring collaborative, evidence-based treatment planning
• Academic Excellence — Fudan University affiliation with a strong research culture and international collaborations
• Cost-Effectiveness — World-class cancer treatment at significantly lower cost than equivalent care in the US, UK, or Australia

The CMCS Patient Journey

1. Initial Inquiry — Share your cancer diagnosis, pathology reports, molecular profiling results, imaging, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review, including molecular report interpretation.
3. Specialist Matching — We identify the most appropriate medical oncologist based on your tumor type and treatment needs.
4. Remote MDT Submission — Where appropriate, we facilitate pre-arrival case review by Zhongshan's tumor board.
5. Priority Scheduling — We secure a consultation with minimal waiting time, including urgent slots for rapidly progressing disease.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Zhongshan Hospital, and Shanghai airport transfers.
7. On-Site Concierge — Bilingual coordinators accompany you throughout your hospital visits, managing registration, translation, and communication with your oncology team.
8. Post-Treatment Follow-Up — Treatment summary translation, response assessment report interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If you are seeking expert cancer care in Shanghai — whether for a second opinion, precision oncology profiling, immunotherapy, or access to clinical trials — CMCS can arrange a specialist consultation with Zhongshan Hospital's medical oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com